GeneDx (WGS) Insider Trading & Ownership $105.13 -0.82 (-0.77%) Closing price 04:00 PM EasternExtended Trading$106.70 +1.57 (+1.49%) As of 07:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock GeneDx (NASDAQ:WGS) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage29.60%Number OfInsiders Buying(Last 12 Months)1Amount OfInsider Buying(Last 12 Months)$5.60MNumber OfInsiders Selling(Last 12 Months)8Amount OfInsider Selling(Last 12 Months)$116.70M Get WGS Insider Trade Alerts Want to know when executives and insiders are buying or selling GeneDx stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address WGS Insider Buying and Selling by Quarter GeneDx Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame Start Date End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails7/29/2025Katherine StuelandCEOSell2,154$105.31$226,837.74 7/29/2025Kevin FeeleyCFOSell388$105.31$40,860.28 7/9/2025Katherine StuelandCEOSell3,220$93.00$299,460.00 7/9/2025Kevin FeeleyCFOSell5,278$93.00$490,854.00 7/1/2025Katherine StuelandCEOSell9,657$90.94$878,207.58 7/1/2025Kevin FeeleyCFOSell1,344$91.12$122,465.28 6/2/2025Kevin FeeleyCFOSell370$71.26$26,366.20 5/8/2025Keith A MeisterDirectorBuy100,000$56.01$5,601,000.00 4/29/2025Katherine StuelandCEOSell2,154$113.09$243,595.86 4/29/2025Kevin FeeleyCFOSell388$113.09$43,878.92 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 4/9/2025Katherine StuelandCEOSell46,594$89.62$4,175,754.28 4/9/2025Kevin FeeleyCFOSell15,516$92.18$1,430,264.88 3/26/2025Katherine StuelandCEOSell46,551$95.62$4,451,206.62 3/26/2025Kevin FeeleyCFOSell8,746$95.61$836,205.06 3/17/2025Katherine StuelandCEOSell10,559$96.71$1,021,160.89 3/17/2025Kevin FeeleyCFOSell3,749$96.71$362,565.79 3/13/2025Katherine StuelandCEOSell1,078$89.44$96,416.32 3/13/2025Kevin FeeleyCFOSell402$90.05$36,200.10 3/10/2025Katherine StuelandCEOSell2,731$94.73$258,707.63 3/10/2025Kevin FeeleyCFOSell922$94.72$87,331.84 1/29/2025Katherine StuelandCEOSell1,657$78.48$130,041.36 1/29/2025Kevin FeeleyCFOSell275$78.48$21,582.00 1/7/2025Katherine StuelandCEOSell51,420$94.48$4,858,161.60 1/7/2025Kevin FeeleyCFOSell35,506$93.82$3,331,172.92 1/2/2025Katherine StuelandCEOSell18,006$78.18$1,407,709.08 1/2/2025Kevin FeeleyCFOSell1,430$76.04$108,737.20 12/16/2024Katherine StuelandCEOSell10,501$76.75$805,951.75 12/16/2024Kevin FeeleyCFOSell3,728$76.75$286,124.00 12/9/2024Katherine StuelandCEOSell3,661$76.37$279,590.57 12/9/2024Kevin FeeleyCFOSell1,137$76.37$86,832.69 12/2/2024Kevin FeeleyCFOSell263$78.39$20,616.57 11/21/2024Kevin FeeleyCFOSell12,019$73.76$886,521.44 11/19/2024Jason RyanDirectorSell31,510$71.28$2,246,032.80 11/18/2024Katherine StuelandCEOSell22,307$70.34$1,569,074.38 11/18/2024School Of Medicine At Mo IcahnMajor ShareholderSell126,782$70.78$8,973,629.96 11/15/2024Katherine StuelandCEOSell23,108$70.48$1,628,651.84 11/15/2024School Of Medicine At Mo IcahnMajor ShareholderSell20,359$69.78$1,420,651.02 10/31/2024School Of Medicine At Mo IcahnMajor ShareholderSell865,800$75.00$64,935,000.00 10/29/2024Katherine StuelandCEOSell2,154$66.60$143,456.40 10/29/2024Kevin FeeleyCFOSell274$66.60$18,248.40 FOUR TRILLION DOLLARS! (Ad)Nvidia just became the first company in history to hit a $4 trillion valuation—surpassing Apple and Microsoft. But one controversial analyst, known for predicting the collapses of Fannie Mae, GM, and others, is issuing a serious warning. He believes Nvidia’s rise has masked a dangerous flaw—and that the stock could fall 50% or more from current levels.Click here to watch his urgent Nvidia exposé before the hype turns to panic.9/9/2024Katherine StuelandCEOSell3,639$33.33$121,287.87 9/9/2024Kevin FeeleyCFOSell895$33.33$29,830.35 9/3/2024Kevin FeeleyCFOSell262$31.71$8,308.02 8/19/2024Opko Health, Inc.Major ShareholderSell50,000$34.49$1,724,500.00 8/15/2024Opko Health, Inc.Major ShareholderSell39,824$33.08$1,317,377.92 8/12/2024Opko Health, Inc.Major ShareholderSell59,787$33.95$2,029,768.65 8/8/2024Opko Health, Inc.Major ShareholderSell100,000$31.82$3,182,000.00 (Data available from 1/1/2013 forward) WGS Insider Trading Activity - Frequently Asked Questions Who is on GeneDx's Insider Roster? The list of insiders at GeneDx includes Casdin Capital, Llc, Isaac Ro, Jason Ryan, Kareem Saad, Karen Ann White, Katherine Stueland, Keith A Meister, Kevin Feeley, Opko Health, Inc., Richard C Pfenniger Jr, Richard Miao, and School Of Medicine At Mo Icahn. Learn more on insiders at WGS. What percentage of GeneDx stock is owned by insiders? 29.60% of GeneDx stock is owned by insiders. Learn more on WGS's insider holdings. Which GeneDx insiders have been buying company stock? The following insiders have purchased WGS shares in the last 24 months: Casdin Capital, Llc ($4,121,270.44), Jason Ryan ($72,062.34), Keith A Meister ($5,601,000.00), and Richard C Pfenniger Jr ($40,400.00). How much insider buying is happening at GeneDx? Insiders have purchased a total of 387,546 WGS shares in the last 24 months for a total of $9,834,732.78 bought. Which GeneDx insiders have been selling company stock? The following insiders have sold WGS shares in the last 24 months: Jason Ryan ($2,246,166.78), Kareem Saad ($37,181.02), Katherine Stueland ($23,194,010.57), Kevin Feeley ($8,451,611.99), Opko Health, Inc. ($23,874,134.15), and School Of Medicine At Mo Icahn ($75,329,280.98). How much insider selling is happening at GeneDx? Insiders have sold a total of 2,209,700 GeneDx shares in the last 24 months for a total of $133,132,385.49 sold. GeneDx Key ExecutivesMs. Katherine A. Stueland (Age 48)President, CEO & Director Compensation: $745.91k9 recent tradesMr. Kevin Feeley (Age 43)Chief Financial Officer Compensation: $488.19k10 recent tradesMs. Karen PonchnerSenior VP & Head of OperationsMr. Eric Olivares Ph.D.Chief Product & Technology OfficerMr. Devin K. Schaffer J.D.M.B.A., General CounselMr. Paul Kruszka M.D.Chief Medical OfficerMs. Melanie DuquetteChief Growth OfficerSabrina DunbarChief of Staff More Insider Trading Tools from MarketBeat Related Companies GH Insider Buying OPCH Insider Buying RDNT Insider Buying BTSG Insider Buying SHC Insider Buying SGRY Insider Buying PRVA Insider Buying ADUS Insider Buying PGNY Insider Buying VCYT Insider Buying Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Strategy Insiders Buy In While Analysts Predict Big UpsideThe Bottom Is in For These 3 Small-Cap Stocks Insiders Are Buying3 Catalysts Driving Plug Power’s Turnaround CaseInsider Selling Hits Market Leaders—Should You Be Worried?Insiders Spent Millions on These 3 Stocks Over the Past 2 Months This page (NASDAQ:WGS) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredFormer CIA Officer Reveals How Gold Saved His Life This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredHow high will gold surge?Weiss Gold Veteran Makes Shocking New Call Weiss expert Sean Brodrick went out on a limb last year and decl...Weiss Ratings | SponsoredShocked one of my clients with thisTrump Schedules Controversial 'Market Reset' for September 30 Behind closed doors, the White House has orde...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GeneDx Holdings Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share GeneDx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
